Evidence Summary

Mebendazole is one of the better-known drug-repurposing candidates in oncology because it combines broad mechanism coverage with a long-established non-cancer safety history.

Research Overview

1. Broad preclinical evidence across ovarian, breast, colorectal, lung, medulloblastoma, glioma, and other cancers

2. Strong mechanistic support for anti-angiogenesis, mitotic disruption, apoptosis, and pathway inhibition

3. Early human clinical work suggests meaningful tolerability even at higher doses

4. Small studies suggest VEGF reduction and possible disease-modifying activity in selected cancers

5. Clinical evidence remains early and heterogeneous

Clinical Application Status

Approved status: Approved as an anti-parasitic drug, not as an approved cancer drug.

Clinical use: Used experimentally in repurposing protocols and investigational integrative oncology settings.

Evidence strength: Strong preclinical evidence with emerging early clinical support, especially for safety and biomarker relevance.

Key Advantages

1. Multi-target action — affects tubulin, angiogenesis, HIFs, Akt, NF-κB, and β-catenin-related survival pathways

2. Repurposed-drug practicality — long clinical history outside oncology and relatively familiar safety profile

3. Angiogenesis inhibition — especially through VEGFR2-related biology

4. Unique ERK duality — suppresses ERK in cancer cells while supporting anti-tumour immune signalling in immune cells

5. CNS relevance — meaningful interest in medulloblastoma and other brain-tumour contexts

Key Considerations

1. Human treatment data is still limited — most evidence remains preclinical or early-stage clinical

2. Dose translation matters — anti-parasitic use and oncology-style use are not the same discussion

3. Combination use requires care — especially in patients on complex active-treatment regimens

4. Interaction review is still essential — even familiar drugs deserve oncology-specific review

5. Sourcing and product strategy still need clearer practical guidance

Bottom line

Mebendazole is one of the most interesting repurposed-drug candidates in oncology. It should be understood as an investigational adjunct with a strong mechanism profile, not as a proven standalone cancer treatment.

Key References

Mebendazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/

Emerging Perspectives on the Antiparasitic Mebendazole as a Cancer Therapy
https://pmc.ncbi.nlm.nih.gov/articles/PMC9862092/

A phase 2a clinical study on the safety and efficacy of mebendazole in cancer
https://www.nature.com/articles/s41598-021-88433-y